Onyvax Limited Release: Onyvax-105 Cancer Vaccine Shows Encouraging Clinical Results In Osteosarcoma Patients After Intensive Chemotherapy 
10/19/2005 5:13:13 PM

London, UK 19 April 2005: Onyvax Limited, the biotechnology company developing novel cancer therapies, today announced the publication of the Phase I/II clinical trial results for Onyvax-105, the company’s investigational anti-cancer immunotherapy also known as 105AD7, in the British Journal of Cancer. Onyvax-105 was invented by a team led by Professor Lindy Durrant at the University of Nottingham with support from Cancer Research UK. The results show that the majority of patients receiving intensive chemotherapy for osteosarcoma can nevertheless mount an immune response to a cancer vaccine approach. Two patients remain free of disease more than 4 yrs after enrolment on the clinical trial, suggesting possible benefit in a small number of cases.